Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neil Rajan

Showing results (61-70 of 95) with videos related to

Pageof 10
Sort By:
Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]|November 14, 2023
Clinical Outcomes in Sebaceous Carcinoma: A Retrospective Two-Center Cohort StudyNour Kibbi, Ursa B Petric, Ghida El-Banna, et al.
Clinical and Experimental Dermatology|February 12, 2022
Porocarcinoma: a reviewJilse Joshy, Khaylen Mistry, Nick J Levell, et al.
Clinical and Experimental Dermatology|April 1, 2023
Epidemiology of porocarcinoma in England 2013-2018: a population-based registry studyJilse Joshy, Birgitta van Bodegraven, Khaylen Mistry, et al.
The British Journal of Dermatology|November 3, 2025
An ontological analysis of a dataset of curated dermatological gene disease associations (G2P-Skin)Tania A Agathangelidi, Luke Carson, Brent J Doolan, et al.
NPJ Genomic Medicine|March 28, 2026
Genotype-based prevalence of Birt-Hogg-Dubé syndrome in the healthcare and genomic registry populations - breaking the 'rare disease' status?Izabela Broniarek, David J Kwiatkowski, Neil Rajan, et al.
Trials|March 9, 2017
Tropomyosin Receptor Antagonism in Cylindromatosis (TRAC), an early phase trial of a topical tropomyosin kinase inhibitor as a treatment for inherited CYLD defective skin tumours: study protocol for a randomised controlled trialAmy Cranston, Deborah D Stocken, Elaine Stamp, et al.
Nature Communications|October 19, 2019
Epigenetic modifiers DNMT3A and BCOR are recurrently mutated in CYLD cutaneous syndromeHelen R Davies, Kirsty Hodgson, Edward Schwalbe, et al.
The Journal of Pathology|March 13, 2016
Overexpression of MYB drives proliferation of CYLD-defective cylindroma cellsNeil Rajan, Mattias K Andersson, Naomi Sinclair, et al.
Clinical and Experimental Dermatology|February 5, 2025
Metastatic malignant cylindroma arising on a background of digenic inheritance of BRCA2 and CYLD pathogenic variants targeted with PARP inhibitionWilliam Fostier, Akhtar Husain, Shirin Namini, et al.
The Journal of Investigative Dermatology|February 9, 2025
Truncating CYLD Pathogenic Variants in CYLD Cutaneous Syndrome Distinctly Influence CYLD Proteostasis and NF-κB SignalingÉva Ádám, Balázs Leitgeb, Judit Danis, et al.
Pageof 10

Showing results (61-70 of 95) with videos related to

Sort By:
Pageof 10
Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]|November 14, 2023
Clinical Outcomes in Sebaceous Carcinoma: A Retrospective Two-Center Cohort StudyNour Kibbi, Ursa B Petric, Ghida El-Banna, et al.
Clinical and Experimental Dermatology|February 12, 2022
Porocarcinoma: a reviewJilse Joshy, Khaylen Mistry, Nick J Levell, et al.
Clinical and Experimental Dermatology|April 1, 2023
Epidemiology of porocarcinoma in England 2013-2018: a population-based registry studyJilse Joshy, Birgitta van Bodegraven, Khaylen Mistry, et al.
The British Journal of Dermatology|November 3, 2025
An ontological analysis of a dataset of curated dermatological gene disease associations (G2P-Skin)Tania A Agathangelidi, Luke Carson, Brent J Doolan, et al.
NPJ Genomic Medicine|March 28, 2026
Genotype-based prevalence of Birt-Hogg-Dubé syndrome in the healthcare and genomic registry populations - breaking the 'rare disease' status?Izabela Broniarek, David J Kwiatkowski, Neil Rajan, et al.
Trials|March 9, 2017
Tropomyosin Receptor Antagonism in Cylindromatosis (TRAC), an early phase trial of a topical tropomyosin kinase inhibitor as a treatment for inherited CYLD defective skin tumours: study protocol for a randomised controlled trialAmy Cranston, Deborah D Stocken, Elaine Stamp, et al.
Nature Communications|October 19, 2019
Epigenetic modifiers DNMT3A and BCOR are recurrently mutated in CYLD cutaneous syndromeHelen R Davies, Kirsty Hodgson, Edward Schwalbe, et al.
The Journal of Pathology|March 13, 2016
Overexpression of MYB drives proliferation of CYLD-defective cylindroma cellsNeil Rajan, Mattias K Andersson, Naomi Sinclair, et al.
Clinical and Experimental Dermatology|February 5, 2025
Metastatic malignant cylindroma arising on a background of digenic inheritance of BRCA2 and CYLD pathogenic variants targeted with PARP inhibitionWilliam Fostier, Akhtar Husain, Shirin Namini, et al.
The Journal of Investigative Dermatology|February 9, 2025
Truncating CYLD Pathogenic Variants in CYLD Cutaneous Syndrome Distinctly Influence CYLD Proteostasis and NF-κB SignalingÉva Ádám, Balázs Leitgeb, Judit Danis, et al.
Pageof 10